Skip to main content
Mile End Institute

AstraZeneca Vaccine: Careless Talk Has Dented Confidence and Uptake in Europe – Dr Jonathan Kennedy

At the start of the year, one of the main causes of the EU’s slow rollout of COVID-19 vaccines was lower than expected supplies from AstraZeneca. Fast forward a few weeks and the EU’s vaccination programme still trails far behind the UK and US, but politicians and those in public health now have something else to worry about: low uptake of the AstraZeneca vaccine. In France, over three-quarters of AstraZeneca vaccines remain unused. In Germany, the figure is two-thirds.

Back to top